Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
about
Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic ApproachesTargeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosisFluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy.Safety of drugs used in the treatment of osteoporosis.Potential pathophysiological mechanisms in osteonecrosis of the jaw.Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatmentAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Rabbiteye blueberry prevents osteoporosis in ovariectomized rats.Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay.Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw.Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking.Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat.Osteoporosis treatment and medication-related osteonecrosis of the jawsOsteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case.Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience.Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.Current and future treatment options in osteoporosis.Adverse drug reactions to osteoporosis treatments.Safety concerns with the long-term management of osteoporosis.Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review.Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.Leucine-rich repeat kinase-1 regulates osteoclast function by modulating RAC1/Cdc42 Small GTPase phosphorylation and activation.The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.It May Seem Inflammatory, but Some T Cells Are Innately Healing to the Bone.Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).Medication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors.Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features.The Effect of RANKL/OPG Balance on Reducing Implant Complications.The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.
P2860
Q28072449-08993F91-440A-4ED8-A5D5-9CA49AB14C03Q28505157-0DD086DF-A820-4090-BC13-EB5A6B3108A0Q33715760-C7A91845-EC75-48B0-AA84-2A487308AC1FQ33949479-90C09946-F3BB-4342-9362-02F89EFE623FQ34162359-365CA27D-4158-4546-8FAF-1E581AABEFABQ34182079-51CA2A88-4D5F-405D-9AB3-2DEC911A977CQ34189582-3B2E5800-83BC-4165-AB3D-07DA22F98DB6Q34544781-4688ED80-A6CC-4997-8FA0-840DC199D0BAQ34870857-3CA0259C-E072-4353-BC8C-956990BE176AQ35570290-E066DBE2-B491-4A4B-94BF-64361A937F7EQ35584866-60804EDE-F26E-4F01-A104-BD3C0935D10EQ35682511-207B0575-BD5F-45A9-83F1-0D34AD7D25EEQ35877630-D47764AD-8D42-4F5E-ADB2-B0DDD078D8D8Q36524611-58548854-7860-4397-B91A-44210DB35BA5Q36667402-482589B3-DD7A-4C52-B59F-BEC072CA9AF8Q36681335-89A29DCC-3812-4E6B-B08C-A705DF7C6F41Q37030229-9F3FF224-20DA-4F41-93F2-CC4FD52C90A9Q37036742-E5514A1D-8A3A-40BA-93F5-BB0B9A959B3EQ37246486-CB02C2D6-74E2-40BC-96B9-D32515C440B8Q37397060-AE922945-D0F1-4299-8E0A-C903972C68FDQ37469798-84391A61-5A06-4C2B-BF0A-9362F71F05FCQ37843715-052BCA17-1232-4E2D-84F6-08DA4434554EQ37973355-8761BF97-D3B9-41F6-AEE2-D90CA28A8EBAQ38101363-ED4C4C21-D517-4D25-AF92-884DEFE58816Q38104993-E19B8174-F1FF-4176-8CB5-210D120313E1Q38193181-FC7F21F2-7A86-4816-8237-5CCCD9AD0FBCQ38339579-DEEAA88C-693D-4F84-AE60-55BF234C1204Q38660112-39E35C52-CE1E-4CCD-8D9F-6993DAE3D677Q38913031-02F752A1-ECB9-48F3-9EB9-AD16BA0126FAQ39143823-A13FF53E-1834-4A56-9B85-B891CC4B2089Q39417130-2B2FEA01-30D2-4F21-858C-95CBD79F146AQ39608998-4AFF30A3-A4EF-4AFB-83CF-C4F826A8438BQ39748470-680BB2F2-B71C-4359-8EEC-B78E4DEC412CQ39776614-6084DA32-4235-48F7-9DB5-38139752A35BQ40324652-1F3DC345-1B53-426A-845F-C5A3FE4B7D60Q41470599-03A9B06C-E39C-4177-95D2-3B3F3A46F34DQ42324262-8D5931F3-2986-4E2F-B714-62904CDDCD48Q42380721-891E3AC3-5752-4C41-95A5-BAFE4B266E20Q47167957-423C8996-2DA5-4381-B64A-A6C01BFFA85EQ48322047-48395C0A-4A00-499B-9C89-29A08C6CDE07
P2860
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@en
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@nl
type
label
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@en
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@nl
prefLabel
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@en
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@nl
P2093
P1476
Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
@en
P2093
K H Taylor
L S Middlefell
P304
P356
10.1016/J.BJOMS.2009.08.030
P577
2010-04-01T00:00:00Z